Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 3, 2006, Pages 784-791

  Sasse, André Deeke ^a,b   De Oliveira Clark, Luciana Gontijo ^a   Sasse, Emma Chen ^a   Clark, Otávio Augusto Camara ^a  

^a Núcleo Brasileiro de Oncologia Baseada Em Evidências   (Brazil)

^b Cidade Universitaria   (Brazil)

Author keywords

Amifostine; Radiation protective agents; Radiotherapy; Side effects; Toxicity

Indexed keywords

DISEASES; DRUG DOSAGE; TOXICITY; TUMORS;

AMIFOSTINE; RADIATION PROTECTIVE AGENTS; SIDE EFFECTS;

RADIOTHERAPY;

AMIFOSTINE;

CLINICAL TRIAL; CYSTITIS; DYSPHAGIA; ESOPHAGITIS; HUMAN; META ANALYSIS; MUCOSA INFLAMMATION; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; REVIEW; SYSTEMATIC REVIEW; XEROSTOMIA;

EID: 31844456882     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.06.023     Document Type: Article

References (44)

1. B. Jeremic, Y. Shibamoto, B. Milicic Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone Lung Cancer 40 2003 317 323
2. D.M. Brizel, J. Overgaard Does amifostine have a role in chemoradiation treatment? Lancet Oncol 4 2003 378 381
3. S.S. Leong, E.H. Tan, K.W. Fong Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable Stage III non-small-cell lung cancer J Clin Oncol 21 2003 1767 1774
4. D. Antonadou, A. Petridis, M. Synodinou Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer Semin Oncol 30 2003 2 9
5. L.M. Schuchter, M.L. Hensley, N.J. Meropol 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants Clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 20 2002 2895 2903
6. J. Bourhis, D. Rosine Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma Semin Oncol 29 2002 61 62
7. M.I. Koukourakis Amifostine Is there evidence of tumor protection? Semin Oncol 30 2003 18 30
8. M. Egger, G.D. Smith, D. Altman Systematic reviews in health care 2nd ed 2001 BMJ Books London
9. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
10. J.P. Higgins, S.G. Thompson, J.J. Deeks Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
11. M. Lenoble [Amifostine Current and future applications in cytoprotection] Bull Cancer 83 1996 773 787
12. H. Niibe, I. Takahashi, N. Mitsuhashi [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors] Nippon Gan Chiryo Gakkai Shi 20 1985 984 993
13. H. Niibe, I. Takahashi, K. Miyaishi [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors] Nippon Gan Chiryo Gakkai Shi 20 1985 994 1001
14. J.M. Yuhas Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) J Natl Cancer Inst 50 1973 69 78
15. E. Bardet, L. Martin, G. Calais Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy Semin Oncol 29 2002 57 60
16. D. Gallardo, A. Mohar, G. Calderillo Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix Int J Gynecol Cancer 9 1999 225 230
17. K. Peters, R. Mucke, D. Hamann Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine? Strahlenther Onkol 175 1999 23 26
18. P.R. Anne Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer Semin Oncol 29 2002 80 83
19. D. Antonadou Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer Semin Radiat Oncol 12 2002 50 58
20. C.L. Bennett, D. Lane, T. Stinson Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer Preliminary results from a randomized phase II clinical trial from Germany Cancer Invest 19 2001 107 113
21. J. Buntzel, J. Schuth, K. Kuttner Radiochemotherapy with amifostine cytoprotection for head and neck cancer Support Care Cancer 6 1998 155 160
22. M.M. Kligerman, T. Liu, Y. Liu Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721 Int J Radiat Oncol Biol Phys 22 1992 799 802
23. R. Komaki, J.S. Lee, B. Kaplan Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable Stage II-III non-small cell lung cancer Preliminary results Semin Radiat Oncol 12 2002 46 49
24. F. Momm, C. Bechtold, V. Rudat Alteration of radiation-induced hematotoxicity by amifostine Int J Radiat Oncol Biol Phys 51 2001 947 951
25. P. Vacha, M. Marx, A. Engel [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial] Strahlenther Onkol 175 1999 18 22
26. T. Wasserman, J.I. Mackowiak, D.M. Brizel Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer Int J Radiat Oncol Biol Phys 48 2000 1035 1039
27. D. Antonadou, N. Coliarakis, M. Synodinou Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer Int J Radiat Oncol Biol Phys 51 2001 915 922
28. D. Antonadou, M. Pepelassi, M. Synodinou Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer Int J Radiat Oncol Biol Phys 52 2002 739 747
29. D. Antonadou, N. Throuvalas, A. Petridis Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 57 2003 402 408
30. H. Athanassiou, D. Antonadou, N. Coliarakis Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas Results of a randomized trial Int J Radiat Oncol Biol Phys 56 2003 1154 1160
31. J. Bourhis, R. De Crevoisier, B. Abdulkarim A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 46 2000 1105 1108
32. M. Braaksma, P. Levendag Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer Subcutaneous amifostine and computed tomography-based target delineation Semin Oncol 29 2002 63 70
33. D.M. Brizel, T.H. Wasserman, M. Henke Phase III randomized trial of amifostine as a radioprotector in head and neck cancer J Clin Oncol 18 2000 3339 3345
34. J. Buntzel, K. Kuttner, D. Frohlich Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer Ann Oncol 9 1998 505 509
35. R. Komaki, J.S. Lee, L. Milas Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer Report of a randomized comparative trial Int J Radiat Oncol Biol Phys 58 2004 1369 1377
36. M.I. Koukourakis, G. Kyrias, S. Kakolyris Subcutaneous administration of amifostine during fractionated radiotherapy A randomized phase II study J Clin Oncol 18 2000 2226 2233
37. J. Kouvaris, V. Kouloulias, E. Malas Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors a phase II randomized study using various toxicity scales and rectosigmoidoscopy Strahlenther Onkol 179 2003 167 174
38. T. Liu, Y. Liu, S. He Use of radiation with or without WR-2721 in advanced rectal cancer Cancer 69 1992 2820 2825
39. N. Senzer A phase III randomized evaluation of amifostine in Stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification Preliminary findings Semin Oncol 29 2002 38 41
40. B. Movsas, C. Scott, C. Langer Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation Radiation Therapy Oncology Group trial 98-01 J Clin Oncol 23 2005 2145 2154
41. K.E. Ohrn, P.O. Sjoden, Y.B. Wahlin Oral health and quality of life among patients with head and neck cancer or haematological malignancies Support Care Cancer 9 2001 528 538
42. P. Juni, D.G. Altman, M. Egger Systematic reviews in health care Assessing the quality of controlled clinical trials BMJ 323 2001 42 46
43. B. Pham, R. Platt, L. McAuley Is there a "best" way to detect and minimize publication bias? An empirical evaluation Eval Health Prof 24 2001 109 125
44. P. Macaskill, S.D. Walter, L. Irwig A comparison of methods to detect publication bias in meta-analysis Stat Med 20 2001 641 654